Coherus Oncology Q3 Sales Were $14.274 Million
Q3 net income was reported as a loss. IBES estimated sales at $16 million.
Story updates
09:25:57 PM UTC
SquawkNews
Coherus Oncology reported third-quarter 2026 revenue from continuing operations of $14.3 million and a net loss from continuing operations of $38.9 million. The company announced plans to prioritize tagmokitug/toripalimab development in esophageal cancer and reduce its workforce by approximately 30…
09:29:53 PM UTC
SquawkNews
Coherus Oncology Q3 sales miss estimates